Navigation Links
Sirtex To Distribute Surefire Medical's Innovative Infusion System in Australia and Asia Pacific Markets

SYDNEY and WESTMINSTER, Colo., June 20, 2013 /PRNewswire/ -- Sirtex Medical Limited (ASX: SRX) and US-based Surefire Medical today announced a sales and marketing partnership to distribute Surefire's range of innovative infusion systems and specialty catheters for the interventional radiology and oncology markets.

The agreement will see Sirtex exclusively distribute the Surefire Medical range of products in the company's rapidly growing Asia Pacific markets including Australia.

Sirtex reported a 30 per cent growth in dose sales of its targeted radiation treatment for liver cancer in the Asia Pacific region at the end of the third quarter ended 31 March 2013.

Rapidly growing Surefire Medical has received regulatory approval in the U.S., Europe, Canada and New Zealand.  Its first-in-class infusion systems are used by numerous top-ranked cancer centers and hospitals in these markets.

The Surefire Infusion System has been designed to enhance the accuracy and delivery of drugs directly to tumors.  Surefire products use a patented microcatheter with an expandable tip. When deployed, the tip dynamically responds to flow conditions to enable more of the embolic agent to reach the intended destination while reducing non-target delivery compared to traditional infusion systems.

The ability to more safely and efficiently deliver embolic agents directly to target tumors marks a significant advance in radiation oncology procedures and in the treatment of liver cancer.

Sirtex Medical Asia Pacific Chief Executive Officer Dr. Burwood Chew said, "Sirtex is constantly looking for new ways to help our customers improve the outcomes of their patients with liver cancer.  We believe this distribution partnership will allow us to provide interventional radiologists and oncologists with a wider range of options that may potentially lead to improved patient outcomes, which is our shared goal."

Surefire Medical CEO Jim Chomas said, "A growing body of positive clinical evidence and the enthusiasm of our increasing user base at hospitals worldwide continue to prove the efficacy of the Surefire line of infusion systems.  The agreement with Sirtex enables our companies to jointly pursue more effective treatment for the rising worldwide incidence of liver cancer."

For further information please refer to and  

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd.

SOURCE Surefire Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Independent Pharmacy Cooperative to Distribute Promescent, Topical Medication for Premature Ejaculation
2. Green Valley Drugs Announces Voluntary Nationwide Recall Of All Lots Of All Sterile Products Compounded, Repackaged, And Distributed By Green Valley Drugs Due To Quality Control Concerns
3. Sigma-Aldrich Corporations Sigma Life Science Business to Distribute Worldwide Olink Biosciences Protein Interaction Analysis Technology
4. GHX Selects MicroStrategy to Offer Healthcare Suppliers Enhanced Access to Distributed Medical-Surgical Market Data
5. Sectra Signs Agreement to Distribute its Breast Imaging PACS With Integrated Cad Software
6. Sectra Signs Agreement to Distribute its Breast Imaging PACS With Integrated Volpara Breast Density Software
7. Surefire Infusion System Used In Potential New Hunger-Reducing Obesity Treatment -- NIH Funds Johns Hopkins Study
8. Study: Surefire Medicals Technology Improves Delivery Of Embolics In Cancer Treatment
9. Surefire Medical, Inc.: Gene McGrevin Joins Surefire Medicals Board of Directors
10. Christopher Mennone Joins Surefire Medical Team As International Business Director
11. Surefire Medicals Infusion System For Embolization Procedures Receives CE Mark Approval
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015 Relmada Therapeutics, Inc. ... treatment of chronic pain, announced today that the company will ... be held December 1-3 at the Luxe Sunset Boulevard Hotel ... Traversa , CEO of Relmada Therapeutics, will present on Thursday, ... Time). . Please register at least 10 ...
(Date:12/1/2015)... 2015 CytRx Corporation (NASDAQ: CYTR ), ... today announced that it has reached its enrollment target ... 3 clinical trial of aldoxorubicin in patients with previously ... be completed in Q1 2016. The Phase 3 trial is ... Protocol Assessment from the FDA at 79 sites in ...
(Date:12/1/2015)... , Dec. 1, 2015  Today, ... the launch of CareFront, a first-of-its-kind population health ... diagnosed with cancer. Designed to be built into ... cancer patients with resources for their care and ... program also offers tools to help patients understand ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... ... Growth in medical payments per workers’ compensation claim in Louisiana slowed from 2011 ... according to a recent study by the Workers Compensation Research Institute (WCRI). , ... per claim with more than seven days of lost time continued to be higher ...
(Date:12/1/2015)... Wayland, MA (PRWEB) , ... December 01, 2015 , ... ... adults has a tattoo — a number even greater among Millennials (a whopping one ... there are more and more people who are dissatisfied with their ink. In fact, ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... technicians must mark the film for accurate interpretation by the radiologist. The marking ... an inventor from Sacramento, Calif., has found a way to alleviate this problem. ...
(Date:12/1/2015)... ... 01, 2015 , ... Next IT Healthcare, the leader in ... this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher ... in the category of Digital Solutions for its innovative, industry-leading product, Alme Health ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning ... results, once a deal is signed. This quick-read guidance suggests that failing ...
Breaking Medicine News(10 mins):